Gland Pharma Limited
Symbol: GLAND.NS
NSE
1708.85
INRTržní cena dnes
42.9265
Poměr P/E
1.6233
Poměr PEG
281.47B
MRK Cap
- 0.00%
Výnos DIV
Gland Pharma Limited (GLAND-NS) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 119605.7 | 38362 | 32427.2 | 24465 | |||||||
balance-sheet.row.short-term-investments | 154862.64 | 19273 | 29268.9 | 19546.8 | |||||||
balance-sheet.row.net-receivables | 22690.46 | 8715.3 | 12514.7 | 12726.8 | |||||||
balance-sheet.row.inventory | 40296.48 | 19453 | 11856.7 | 12751.7 | |||||||
balance-sheet.row.other-current-assets | 5282.69 | 2477.8 | 1722.3 | 1292.9 | |||||||
balance-sheet.row.total-current-assets | 187875.33 | 69008.1 | 58520.8 | 51236.4 | |||||||
balance-sheet.row.property-plant-equipment-net | 51493.3 | 17361 | 17269 | 13244.4 | |||||||
balance-sheet.row.goodwill | 4555.95 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 1656.81 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 6212.76 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.long-term-investments | -16835.11 | -733.7 | 2000 | -19477.3 | |||||||
balance-sheet.row.tax-assets | 1402.64 | 958.9 | -415.1 | 0 | |||||||
balance-sheet.row.other-non-current-assets | -39445.19 | 1064.4 | 836.1 | 19957.3 | |||||||
balance-sheet.row.total-non-current-assets | 2828.4 | 18767.3 | 19815.4 | 13724.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 190703.73 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.account-payables | 15655.98 | 5873.5 | 4628.5 | 4007.3 | |||||||
balance-sheet.row.short-term-debt | 2102.99 | 7.1 | 2.6 | 3 | |||||||
balance-sheet.row.tax-payables | 624.79 | 9.8 | 179.8 | 286.9 | |||||||
balance-sheet.row.long-term-debt-total | 1511.84 | 37.4 | 44.8 | 47 | |||||||
Deferred Revenue Non Current | 1298.89 | 49.9 | 55.5 | 56.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 2180.49 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 3290.63 | 924.7 | 552.6 | 63.3 | |||||||
balance-sheet.row.total-non-current-liabilities | 5396.07 | 896.8 | 939.8 | 803.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 449.53 | 6.3 | 8.1 | 9.3 | |||||||
balance-sheet.row.total-liab | 28049.42 | 8188.1 | 6760 | 5928.4 | |||||||
balance-sheet.row.preferred-stock | 15.59 | 15.6 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 329.4 | 164.7 | 164.3 | 163.6 | |||||||
balance-sheet.row.retained-earnings | 60153.88 | 60153.9 | 52343.4 | 40226.8 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 245541.11 | -15.6 | 114.5 | 240.9 | |||||||
balance-sheet.row.other-total-stockholders-equity | 19268.64 | 19268.6 | 18953.9 | 18401.1 | |||||||
balance-sheet.row.total-stockholders-equity | 325308.62 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 353358.04 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 325308.62 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 353358.04 | - | - | - | |||||||
Total Investments | 138027.53 | 18539.3 | 2000 | 69.5 | |||||||
balance-sheet.row.total-debt | 3614.83 | 44.5 | 47.4 | 50 | |||||||
balance-sheet.row.net-debt | 38871.77 | -19044.4 | -3110.8 | -4868.3 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 6587.23 | 10545.8 | 16185.5 | 13348.1 | |||||||
cash-flows.row.depreciation-and-amortization | 2894.99 | 1467.4 | 1103 | 987.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -4143.8 | -3254 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 46.2 | 155.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -4179.4 | -3930.8 | -4357.6 | |||||||
cash-flows.row.account-receivables | 0 | 1440 | -4195.7 | -602 | |||||||
cash-flows.row.inventory | 0 | -7596.3 | 895 | -5188.9 | |||||||
cash-flows.row.account-payables | 0 | 1209.8 | 658.5 | 1428.2 | |||||||
cash-flows.row.other-working-capital | 0 | 767.2 | -1288.6 | 5.1 | |||||||
cash-flows.row.other-non-cash-items | -6587.23 | -4194.1 | -1352.4 | -830.4 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 5789.98 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.acquisitions-net | 0 | -12705.6 | 6117.2 | 4.3 | |||||||
cash-flows.row.purchases-of-investments | 0 | -4699.8 | -16818.1 | -13575.9 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 17405.4 | 10700.9 | -4.3 | |||||||
cash-flows.row.other-investing-activites | 0 | 14313.1 | -4805 | 623.7 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 12081.9 | -10026.2 | -15240 | |||||||
cash-flows.row.debt-repayment | 0 | -1.1 | -1.4 | -8.9 | |||||||
cash-flows.row.common-stock-issued | 0 | 215 | 385.5 | 12418.1 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -64.7 | -35.2 | -24.6 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 149.2 | 349 | 12384.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 30 | 33.1 | 35.8 | |||||||
cash-flows.row.net-change-in-cash | 5789.98 | 15900.8 | -1736.4 | 3229.7 | |||||||
cash-flows.row.cash-at-end-of-period | 51207.44 | 19089 | 3188.2 | 4924.6 | |||||||
cash-flows.row.cash-at-beginning-of-period | 45417.46 | 3188.2 | 4924.6 | 1695 | |||||||
cash-flows.row.operating-cash-flow | 5789.98 | 3639.7 | 7907.7 | 6049.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.free-cash-flow | 5789.98 | 1408.5 | 2686.5 | 3761.5 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 49122.83 | 36246 | 43841.4 | 34236.4 | |||||||
income-statement-row.row.cost-of-revenue | 19385.47 | 16854.3 | 21092.2 | 14918.7 | |||||||
income-statement-row.row.gross-profit | 29737.36 | 19391.7 | 22749.3 | 19317.6 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 2016 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 1670.27 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.operating-expenses | 21203.94 | 10611.5 | 8745.5 | 7280.4 | |||||||
income-statement-row.row.cost-and-expenses | 40589.41 | 27465.7 | 29837.7 | 22199.2 | |||||||
income-statement-row.row.interest-income | 1783.74 | 1794.2 | 1386.5 | 859.5 | |||||||
income-statement-row.row.interest-expense | 184.45 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 190.97 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 1670.27 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.total-operating-expenses | 190.97 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.interest-expense | 184.45 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.depreciation-and-amortization | 2894.99 | 1467.4 | 1103 | 987.8 | |||||||
income-statement-row.row.ebitda-caps | 12534.07 | - | - | - | |||||||
income-statement-row.row.operating-income | 9263.66 | 8844.4 | 14000.3 | 12034.5 | |||||||
income-statement-row.row.income-before-tax | 9454.63 | 10545.8 | 16185.5 | 13348.1 | |||||||
income-statement-row.row.income-tax-expense | 2867.4 | 2735.4 | 4068.9 | 3378.5 | |||||||
income-statement-row.row.net-income | 6587.23 | 7810.4 | 12116.6 | 9969.6 |
Často kladené otázky
Co je Gland Pharma Limited (GLAND.NS) celková aktiva?
Gland Pharma Limited (GLAND.NS) celková aktiva jsou 87775350000.000.
Jaký je roční obrat podniku?
Roční příjmy jsou 29185790000.000.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.605.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je 35.155.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.134.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.189.
Co je Gland Pharma Limited (GLAND.NS) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 7810430000.000.
Jaký je celkový dluh podniku?
Celkový dluh je 44530000.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 10611470000.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou -21447340000.000.